Michigan Medicine details treatment-access concerns as 7-OH policy shifts

Why it matters

The article connects changing availability of synthetic kratom-related products with a practical treatment question: whether people who develop dependence can access care. It points patients and clinicians toward substance-use treatment and emergency-response resources.

The big picture

Federal action effective August 26 temporarily placed mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I. The article says 7-OH itself was not federally scheduled at the time of publication, although the DEA had reopened comments on a proposed threshold-based action. It distinguishes these products from natural leaf kratom while describing state and local restrictions that vary across the country.

Key findings

• Michigan Medicine reports that the federal order applies to mitragynine pseudoindoxyl, MGM-15 and MGM-16 from August 26, 2026
• The article says products containing 7-OH but none of those three compounds could still technically be sold where state law allowed at publication
• A Michigan House bill to ban 7-OH and kratom products had passed the House but had not been taken up by the state Senate
• Clinician Eliza Hutchinson reported that some patients contacted her clinic after hearing products might leave retail shelves
• The article identifies buprenorphine, naloxone and emergency care as relevant elements of clinical response to opioid-like effects and substance-use concerns

What they say

Eliza Hutchinson, M.D., said: “Regardless of the outcome of the DEA scheduling decision, the need for treatment access and education is increasing.”

Bottom line

**Policy changes may alter product availability quickly, so treatment access and accurate clinical information remain central for people affected by 7-OH or related synthetic opioids.**